Creating and Restoring Equal Access to Equivalent Samples Act of 2019 : report (to accompany H.R. 965) (including cost estimate of the Congressional Budget Office).

Preserve Access to Affordable Generics and Biosimilars Act : report together with additional views (to accompany H.R. 2375) (including cost estimate of the Congressional Budget Office).
Published: (2020)

Paying off generics to prevent competition with brand name drugs : should it be prohibited? : hearing before the Committee on the Judiciary, United States Senate, One Hundred Tenth Congress, first session, January 17, 2007.
Published: (2007)

Paying off generics to prevent competition with brand name drugs : should it be prohibited? : hearing before the Committee on the Judiciary, United States Senate, One Hundred Tenth Congress, first session, January 17, 2007.
Published: (2007)

Entry threats and pricing in the generic drug industry /
by: Wendling, Brett
Published: (2010)

The effect of generic drug competition on generic drug prices during the Hatch-Waxman 180-day exclusivity period /
by: Olson, Luke M., et al.
Published: (2013)

Preserve Access to Affordable Generics Act : report together with minority views (to accompany S. 369) (including cost estimate of the Congressional Budget Office).
Published: (2010)

How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry.
Published: (1998)

How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry.
Published: (1998)

Drug pricing : research on savings from generic drug use /
by: Dicken, John E.
Published: (2012)

Closing the coverage gap : Medicare prescription drugs are becoming more affordable.
Published: (2015)

Prescription drugs : price tends for frequently used brand and generic drugs from 2000 through 2004 : report to congressional requesters.
Published: (2005)

Trends in brand name and generic prescribed medicine utilization and expenditures, 1999 to 2003 /
by: Stagnitti, Marie N.
Published: (2006)

Why are some generic drugs skyrocketing in price? : hearing before the Subcommittee on Primary Health and Aging of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Thirteenth Congress, second session, on examining the pricing of generic drugs, November 20, 2014.
Published: (2017)

Expanding the use of generic drugs.
Published: (2010)

Generic drug user fee amendments : accelerating patient access to generic drugs : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session ... January 28, 2016.
Published: (2018)

Making Objective Drug Evidence Revisions for New Labeling Act of 2020 : report (to accompany H.R. 5668) (including cost estimate of the Congressional Budget Office).
Published: (2020)

Competition in the drug industry : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, Ninety-seventh Congress, first session, March 10, 1981.
Published: (1981)

Examining the Senate and House versions of the "Greater Access to Affordable Pharmaceuticals Act" : hearing before the Committee on the Judiciary, United States Senate, One Hundred Eighth Congress, first session, August 1, 2003.
Published: (2004)

Examining the Senate and House versions of the "Greater Access to Affordable Pharmaceuticals Act" : hearing before the Committee on the Judiciary, United States Senate, One Hundred Eighth Congress, first session, August 1, 2003.
Published: (2004)

Drug pricing : poor prescription for consumers and taxpayers? : hearing before the Committee on Governmental Affairs, United States Senate, One Hundred Third Congress, second session, July 27, 1994.
Published: (1995)

Special report of the U.S. Senate Special Committee on Aging on the sudden price spikes in off-patent prescription drugs : the monopoly business model that harms patients, taxpayers, and the U.S. health system.
Published: (2016)

Closing the gaps in Hatch-Waxman : assuring greater access to affordable pharmaceuticals : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Seventh Congress, second session, on examining certain provisions of the 1984 Drug Price Competition and Patent Term Restoration Act, known as the Hatch-Waxman Act, assuring greater access to affordable pharmaceuticals, May 8, 2002.
Published: (2002)

Closing the gaps in Hatch-Waxman : assuring greater access to affordable pharmaceuticals : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Seventh Congress, second session, on examining certain provisions of the 1984 Drug Price Competition and Patent Term Restoration Act, known as the Hatch-Waxman Act, assuring greater access to affordable pharmaceuticals, May 8, 2002.
Published: (2002)

Medicare Part D, prescription drug benefit : increasing use and access of affordable prescription drugs : a report of the Special Committee on Aging, United States Senate.
Published: (2014)

More Efficient Tools to Realize Information for Consumers Act : report (to accompany H.R. 2296).
Published: (2019)

Developments in the prescription drug market : oversight : hearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fourteenth Congress, second session, February 4, 2016.
Published: (2017)

Protecting Consumer Access to Generic Drugs Act of 2019 : report (to accompany H.R. 1499) (including cost estimate of the Congressional Budget Office).
Published: (2019)

Examining the impact of voluntary restricted distribution systems in the pharmaceutical supply chain : hearing before the Subcommittee on Healthcare, Benefits, and Administrative Rules of the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fifteenth Congress, first session, March 22, 2017.
Published: (2017)

Skyrocketing prescription drug costs : effects on senior citizens : hearing before the Special Committee on Aging, United States Senate, One Hundred Second Congress, second session, Lewiston, ME, April 15, 1992.
Published: (1993)

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act : report (to accompany H.R 2374) (Including cost estimate of the Congressional Budget Office).
Published: (2020)

Authorized generic drugs : short-term effects and long-term impact.
Published: (2011)

Competitive problems in the pharmaceutical drug industry : hearing before the Subcommittee on Antitrust, Monopolas printed], and Business Rights of the Committee on the Judiciary, United States Senate, One Hundredth Congress, first session, on the generic drug industry and its concerns with respect to competition from the brand name manufacturers, October 21, 1987.
Published: (1989)

The generic drug maze : speeding access to affordable life-saving drugs : hearing before the Special Committee on Aging, United States Senate, One Hundred Ninth Congress, second session, Washington, DC, July 20, 2006.
Published: (2006)

The generic drug maze : speeding access to affordable life-saving drugs : hearing before the Special Committee on Aging, United States Senate, One Hundred Ninth Congress, second session, Washington, DC, July 20, 2006.
Published: (2006)

Examining issues related to competition in the pharmaceutical marketplace : a review of the FTC report, Generic drug entry prior to patent expiration : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, October 9, 2002.
Published: (2002)

Full committee hearing on Medicaid drug reimbursements : are CMS cuts bad medicine for small businesses and beneficiaries? /
Published: (2007)